FINNCURE helps pharmaceutical and biotechnology companies solve one of drug
development’s biggest challenges: delivering therapeutic compounds safely and efficiently to the right cells.

Our receptor-targeted carrier platform enables precise delivery of therapeutic compounds to target cells. In selected applications, receptor binding itself can also provide therapeutic benefit by blocking cell-surface receptors and viral entry. 

The platform has been validated in independent preclinical studies, with findings published in Nano Letters. Our technology is further supported by a growing IP portfolio, including 5 issued U.S. patents and multiple pending applications. 

While our current development focuses on lipid nanoparticles (LNPs), the platform is adaptable to other synthetic carrier systems. 

FINNCURE is supported by a network of experts across scientific research, preclinical development, manufacturing, regulatory affairs, and intellectual property. 

We are actively seeking partnerships with pharmaceutical and biotechnology companies developing therapies that could benefit from our targeted delivery technology.

FINNCURE

Org chart

Teams

Offices

FINNCURE

Org chart

Teams

Offices

Related companies